Impedimed Limited ( (AU:IPD) ) just unveiled an update.
ImpediMed Limited has announced a change in the address of its Sydney share registry office, which is now located at Liberty Place, Level 41, 161 Castlereagh Street, Sydney NSW 2000. This move is part of the company’s ongoing operational adjustments, although the telephone numbers and postal address remain unchanged. This update is approved by the Company Secretary and reflects ImpediMed’s commitment to maintaining efficient operations and communication with stakeholders.
More about Impedimed Limited
ImpediMed Limited, founded in Brisbane, Australia, operates in the medical technology industry, focusing on bioimpedance spectroscopy (BIS) technology to enhance patient health. The company produces the SOZO Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for various conditions like lymphoedema, heart failure, and protein calorie malnutrition. ImpediMed is notable for its FDA-cleared technology for lymphoedema assessment and operates on a SaaS subscription model, targeting the cancer-related lymphoedema market.
YTD Price Performance: -44.44%
Average Trading Volume: 67,256
Technical Sentiment Signal: Strong Buy
Current Market Cap: $45.86M
For a thorough assessment of IPD stock, go to TipRanks’ Stock Analysis page.